Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Onconic Therapeutics Prepares for Global Phase 2 of Novel Anticancer Drug ‘Nesuparib’… “Clinical Plan to Submit to FDA by Year-End”

Summary by 조선일보
BioUSA: Onconic Therapeutics Prepares for Global Phase 2 Clinical Trials of Novel Anticancer Drug Nesuparib; Clinical Plan to be Submitted to FDA by Year-End. CEO Kim Jon Presents at BioUSA; Discussions on Technology Export and Commercialization with Global Pharmaceutical Companies. Onconic Therapeutics, a subsidiary of Jeil Pharmaceutical, [plans] domestic clinical trials for the next-generation dual-target anticancer drug Nesuparib, including …

1 Articles

조선일보조선일보
Lean Right

Onconic Therapeutics Prepares for Global Phase 2 of Novel Anticancer Drug ‘Nesuparib’… “Clinical Plan to Submit to FDA by Year-End”

BioUSA: Onconic Therapeutics Prepares for Global Phase 2 Clinical Trials of Novel Anticancer Drug Nesuparib; Clinical Plan to be Submitted to FDA by Year-End. CEO Kim Jon Presents at BioUSA; Discussions on Technology Export and Commercialization with Global Pharmaceutical Companies. Onconic Therapeutics, a subsidiary of Jeil Pharmaceutical, [plans] domestic clinical trials for the next-generation dual-target anticancer drug Nesuparib, including …

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Right
100% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

조선일보 broke the news on Thursday, June 25, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

FDA icon

FDA

Economy icon

Economy

South Korea icon

South Korea

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal